The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson’s disease
作者
William C. Koller,Matthew B. Stern,Ray L. Watts
出处
期刊:Neurology [Lippincott Williams & Wilkins] 日期:2004-10-12卷期号:63 (7_suppl_2)被引量:1
标识
DOI:10.1212/wnl.63.7_suppl_2.s1
摘要
Monoamine oxidase (MAO) inhibitors as a potential therapy in Parkinson’s disease (PD) have been in use since the time levodopa first underwent clinical trials for the treatment of PD. During that period, nonselective MAO inhibitors were used in an attempt to potentiate the effects of levodopa, but they were largely abandoned because of their potential to cause hypertensive crises (the “cheese effect”) and the resulting stringent dietary restrictions.
In the mid 1960s selegiline was introduced as a novel compound capable of selectively inhibiting the B form …